Adams Diversified Equity Fund’s Enanta Pharmaceuticals ENTA Stock Holding History

Adams Diversified Equity Fund’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,000	Closed	-$84K	–	126
2019 Q2	$84K	Sell	1,000 -1,300	-57%	-$117K	﹤0.01%	214
2019 Q1	$220K	Sell	2,300 -2,600	-53%	-$233K	0.01%	194
2018 Q4	$347K	Sell	4,900 -200	-4%	-$15.3K	0.02%	205
2018 Q3	$436K	Sell	5,100 -300	-6%	-$30.1K	0.02%	205
2018 Q2	$626K	Sell	5,400 -5,400	-50%	-$539K	0.03%	176
2018 Q1	$874K	Hold	10,800	–	–	0.05%	109
2017 Q4	$634K	Sell	10,800 -9,200	-46%	-$461K	0.03%	176
2017 Q3	$936K	Sell	20,000 -700	-3%	-$28.1K	0.05%	158
2017 Q2	$745K	Sell	20,700 -3,800	-16%	-$122K	0.04%	181
2017 Q1	$755K	Buy	24,500 +700	+3%	+$21.8K	0.04%	198
2016 Q4	$797K	Buy	23,800 +15,000	+170%	+$430K	0.05%	188
2016 Q3	$194K	Hold	8,800	–	–	0.01%	196
2016 Q2	$194K	Buy	+8,800	New	+$230K	0.01%	196

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Adams Diversified Equity Fund's ENTA Position: Q3 2019 in Review

Adams Diversified Equity Fund sold out of Enanta Pharmaceuticals (ENTA) in Q3 2019, closing a stake of 1,000 shares — an estimated $84K sold.

Adams Diversified Equity Fund first reported a position in ENTA in Q2 2016 and held it in 13 quarters. The position peaked at $936K in Q3 2017. 176 funds tracked by Wall St. Rank hold ENTA as of Q3 2019.

Adams Diversified Equity Fund reported no remaining Enanta Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Adams Diversified Equity Fund sold 1,000 Enanta Pharmaceuticals shares in Q3 2019, an estimated $84K.
Adams Diversified Equity Fund first reported a position in Enanta Pharmaceuticals in Q2 2016 and held it in 13 quarters.
Adams Diversified Equity Fund's Enanta Pharmaceuticals position peaked at $936K in Q3 2017.
176 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2019.

Based on Adams Diversified Equity Fund's 13F filing for Q3 2019, filed 28 Oct 2019.